ArticleAmerican journal of translational research2026
Synergistic combination of taxifolin and baicalein protects against alloxan-induced diabetic cardiomyopathy by mitigating oxidative stress through the Nrf2/HO-1 signaling pathway.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the cardioprotective effects of taxifolin (TXN) and baicalein (BCN) in an alloxan-induced diabetic rat model.
methodsDiabetic rats were treated with TXN, BCN, or their combination for 30 days. Blood glucose, lipid profile, cardiac enzymes, oxidative stress markers, and gene expression were assessed. Histopathologic and immunohistochemical analyses were performed to evaluate cardiac structure and protein expression.
resultsTXN and BCN significantly reduced blood glucose levels, improved lipid profiles, and decreased oxidative stress in diabetic rats. They also enhanced nuclear factor erythroid 2-related factor 2 (Nrf2) signaling and upregulated antioxidant gene expression. Histologic analysis revealed reduced myocardial damage and fibrosis in treated rats.
conclusionTXN and BCN exhibit cardioprotective effects in diabetic rats by improving glucose metabolism, modulating lipid profiles, and enhancing antioxidant defense through the Nrf2 signaling pathway. These findings suggest that TXN and BCN hold promise as potential therapeutic agents for the prevention and treatment of diabetic cardiomyopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.